Porcine Vaccine Market Report 2026

Porcine Vaccine Market Overview

• Porcine Vaccine market size has reached to $2.05 billion in 2025 • Expected to grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Pork Consumption Fuels Growth In The Porcine Vaccine Market • Market Trend: Strategic Partnerships In The Porcine Vaccine Market Pirbright And TVG Collaborate To Develop Innovative African Swine Fever Vaccines • North America was the largest region in 2025.

What Is Covered Under Porcine Vaccine Market?

Porcine vaccines are a medical and pharmaceutical treatment that improves the health of pigs by shielding them from different bacteria, viruses, and other infections. It is used to increase the efficacy of protecting pigs from harmful ailments while increasing the output of top-notch meat for human consumption. The major technologies used in porcine vaccines are inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. An inactivated vaccine is a type of vaccine made from a virus or bacterium that has been killed or inactivated, meaning it is no longer capable of replicating or causing disease. Inactivated porcine vaccines stimulate an immune response to protect the pigs against later natural infection with the organism from which the vaccine was administered. It is used in various disease such as diarrhea, swine influenza, arthritis, bordatella rhinitis, porcine reproductive and respiratory virus (PRRSV), porcine circovirus-associated disease (PCVAD) and others, that are used in hospitals and hog or pig production farm.

What Is The Porcine Vaccine Market Growth Forecast?

The porcine vaccine market size is expected to see strong growth in the next few years. It will grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to growth of recombinant and dna vaccines, adoption of precision veterinary medicine, increased focus on herd immunity programs, technological advancements in vaccine delivery systems, rising government initiatives for livestock health. Major trends in the forecast period include adoption of multi-strain vaccines for pigs, increasing focus on disease prevention in swine herds, rising investments in swine immunization programs, integration of veterinary advisory services with farms, expansion of cold chain infrastructure for vaccine distribution.

Global Porcine Vaccine Market Segmentation

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines 2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications 3) By End User: Veterinary Hospitals, Hog Or Pig Production Farm Subsegments: 1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines 2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines 3) By Toxoid Vaccines: Inactivated Toxins 4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines 5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines 6) By DNA Vaccines: Plasmid DNA Vaccines

What Is The Driver Of The Porcine Vaccine Market?

The increasing pork consumption is expected to propel the growth of the porcine vaccine market going forward. Pork consumption is the quantity of pork meat that people or groups eat in a specific amount of time. The consumption of pork has increased in tandem with the growing global population and the growing demand for protein. The porcine vaccine market supports increasing pork consumption, as vaccines help prevent diseases in pigs, improve herd health, and ensure a stable supply of safe and high-quality pork products. For instance, in July 2024, according to the INAPORC (Interprofession Nationale Porcine), a France-based national pork association, in 2023, pork was still the most consumed meat in France, with about 30.6 kg per person per year. Therefore, increasing pork consumption is driving the growth of the porcine vaccine industry.

Key Players In The Global Porcine Vaccine Market

Major companies operating in the porcine vaccine market are Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., IDT Biologika GmbH, Biogénesis Bagó, Aptimmune Biologics Inc., Virbac S.A., Vaxxinova International BV, Bioveta a.s., Indian Immunologicals Limited, KM Biologics, Addison Biological Laboratory, Colorado Serum Company, CAHIC China Animal Husbandry Industry Co, Tecon, Hile Bio, WINSUN

Global Porcine Vaccine Market Trends and Insights

Major companies operating in the porcine vaccine market are adapting strategic partnerships to enhance their research and development capabilities and strengthen their competitive position in the rapidly evolving animal health industry. The collaboration makes use of TVG's experience in vaccine technology and Pirbright's expertise in African swine fever (ASF) research. The goal of this partnership is to improve the vaccine development process and develop novel approaches that have the potential to greatly improve swine health. For instance, in May 2024, The Pirbright Institute, a UK-based research institute, partnered with The Vaccine Group (TVG), a UK-based company, to develop a vaccine for African swine fever (ASF), The research aims to develop vaccines to prevent African swine fever (ASF) by using bovine herpesvirus 4 (BoHV-4) as a foundation. This method takes advantage of the latest breakthroughs in ASF vaccine research and pig immunology to design more efficient vaccines. The initiative is funded by the U.K.'s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

What Are Latest Mergers And Acquisitions In The Porcine Vaccine Market?

In July 2024, Merck Animal Health Inc., a US-based company, acquired Elanco for an undisclosed amount. With this acquisition, Merck Animal Health aims to expand its portfolio by incorporating Elanco's expertise in providing porcine vaccines. Elanco Animal Health Inc is a US-based company that offers porcine vaccines.

Regional Outlook

North America is the largest region in the porcine vaccine market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Porcine Vaccine Market?

The porcine vaccines market consists of sales of antibacterial vaccines and antiviral vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.